NCT05821101View on ClinicalTrials.gov

Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

June 30, 2026

Conditions
Aphakia, Postcataract
Interventions
DEVICE

Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.

Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).

Trial Locations (1)

94301

Palo Alto Medical Foundation, Palo Alto

Sponsors

Collaborators (1)

Alcon Research
All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Debbie S. Kuo, MD

OTHER

NCT05821101 - Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach | Biotech Hunter | Biotech Hunter